Background: Vitamin B 12 deficiency occurs frequently, especially among the elderly. However, screening for vitamin B 12 deficiency is hampered by poor sensitivity of the existing total vitamin B 12 assay. Methylmalonic acid (MMA) is considered as the most representative indicator of metabolic vitamin B 12 deficiency and is used as such in this study. The aim of this study was to validate the clinical usefulness of holotranscobalamin (holoTC) as an initial screening assay for metabolic vitamin B 12 deficiency in a mixed patient population. Methods: Three hundred and sixty blood samples were collected by five Dutch hospitals. Vitamin B 12 and holoTC in serum were measured (AxSYM; Abbott). MMA in serum was measured by tandem mass spectrometry (LC-MS/MS). Results: Receiver operating curve (ROC) analysis demonstrated a greater area under the curve (AUC) for holoTC than for vitamin B 12 in detecting vitamin B 12 deficiency characterized by three predefined cut-off levels of MMA. A cut-off value of 32 pmol/L of holoTC resulted in the highest sensitivity (83%) with acceptable specificity (60%) in detecting MMA concentrations above 0.45 mmol/L. The combination of vitamin B 12 and holoTC did not improve diagnostic accuracy at this cut-off level. Conclusions: HoloTC has a better diagnostic accuracy than vitamin B 12 and can replace the existing vitamin B 12 assay as a primary screening test in patients suspected of vitamin B 12 deficiency. Critical evaluation of cut-off values of holoTC indicated that a cut-off value of 32 pmol/L can be considered in screening for metabolic vitamin B 12 deficiency (defined by MMA . 0.45mmol/L) in a mixed patient population.
Introduction
Vitamin B 12 deficiency occurs frequently in the elderly and can be caused by several factors like impaired absorption or inadequate dietary intake. 1 Humans cannot synthesize vitamin B 12 (i.e. cobalamin) and therefore it has to be obtained through the diet. Vitamin B 12 deficiency is commonly asymptomatic in the early stages, but can later on be associated with macrocytic anaemia and typical neurological symptoms, either alone or in combination. 2, 3 These symptoms are, however, far from specific and are variable in their presence and severity. Establishing vitamin B 12 deficiency on objective grounds is therefore challenging. In most studies, the measurement of the metabolic consequence of vitamin B 12 deficiency, an increase in methylmalonic acid (MMA), has been applied. 4 -7 A shortage of vitamin B 12 leads to insufficient activity of the enzyme methylmalonyl-CoA mutase, and hence to accumulation of its substrate MMA.
MMA is considered as the gold standard in the diagnosis of metabolic vitamin B 12 deficiency. 8 However, MMA can only be measured by complex, specialized methods which are relatively expensive. Vitamin B 12 measurement in serum is frequently used as a first-line assay in screening for vitamin B 12 deficiency. Diagnostic accuracy of this assay is hampered Annals of Clinical Biochemistry 2012; 49: 184 -189 by a low sensitivity, which results in a relatively large amount of false negatives. 5 Recently, the holotranscobalamin (holoTC) assay was implemented on an automated analyser (AxSYM Active B 12 assay; Abbott, Hoofddorp, The Netherlands) facilitating high-throughput holoTC measurements in standard clinical chemistry laboratories. 9 Several studies have assessed the diagnostic accuracy of holoTC in relation to metabolic vitamin B 12 deficiency. 4 -7 Most studies reported comparable or modestly superior diagnostic accuracy of holoTC based on receiver operating curve (ROC) analysis. However, large discrepancies exist with regard to the choice of cut-off value for holoTC (range: 20-45 pmol/L), which makes data interpretation difficult. In addition, different populations were studied, like the elderly, vegetarians and healthy controls, which might have influenced the choice of cut-off value. 4, 5, 7 In this study, we validated the diagnostic accuracy of holoTC as a screening test for metabolic vitamin B 12 deficiency in patients suspected of vitamin B 12 deficiency and compared this with vitamin B 12 in a Dutch multicenter study using clinical samples for which vitamin B 12 was requested.
Material and methods

Study population
Patient samples were collected between November 2006 and July 2007 from clinical chemistry laboratories in the Netherlands. Originally, each centre aimed to collect samples of 250 patients of whom vitamin B 12 was requested. Each centre was asked to select 20 patients with a vitamin B 12 concentration below 100 pmol/L, 80 patients with vitamin B 12 between 100 and 200 pmol/L, 100 patients with vitamin B 12 between 200 and 300 pmol/L and 50 patients with vitamin B 12 above 300 pmol/L. After determination of vitamin B 12 in serum, the samples were stored at 2808C. When sample collection was completed, frozen samples were sent on dry ice to the Erasmus MC and were stored at 2808C until further analysis.
Individuals were selected on the basis of age (!18 years), normal renal function (estimated glomerular filtration rate [eGFR] !60 mL/min/1.73 m 2 ) and availability of vitamin B 12 , holoTC and MMA measurements in serum. In total, 360 individuals could be included in ROC analysis, which were collected at Erasmus MC (n ¼ 148), Meander MC (n ¼ 4), UMC Groningen (n ¼ 61), Gelre Hospitals (n ¼ 62) and Star-MDC (n ¼ 85). Informed consent was not obtained as leftover material from routine analysis was used for this study which was processed anonymously.
Laboratory methods
Serum vitamin B 12 was determined in each sample by the same type of analyser (AxSYM; Abbott,) at the Erasmus MC (n ¼ 299 samples) and at the UMC Groningen (n ¼ 61 samples). HoloTC was determined in each serum sample at the Erasmus MC by the AxSYM analyser (Abbott). Analytical imprecision (i.e. within-run and total imprecision were below 8% for three pools with different concentrations of holoTC [i.e. 20, 40 and 80 pmol/L]). The assay was linear in the range from 5 to 86 pmol/L. Samples with holoTC values above 86 pmol/L were diluted with saline to obtain values within the linear range. Serum MMA was measured by tandem mass spectrometry (LC-MS/MS) at the Erasmus MC. 10 The laboratory participates in the European Research Network for evaluation and improvement of screening, Diagnosis and treatment of Inherited disorders of Metabolism (ERNDIM; 0 to þ0.5SD from consensus MMA concentration) for external quality control.
The 95% reference range of holoTC, vitamin B 12 and MMA was determined in 100 healthy blood bank donors (i.e. 50 men and 50 women) at the Erasmus MC and was 21 -117 pmol/L for holoTC, 145-637 pmol/L for vitamin B 12 and 0.09 -0.45 mmol/L for MMA. Three predefined cut-off values of MMA were applied to define metabolic vitamin B 12 deficiency: MMA . 0.32mmol/L (i.e. 90th percentile); serum MMA . 0.45 mmol/L (i.e. 97.5th percentile); and MMA . 0.77 mmol/L (i.e. 99th percentile).
Haemoglobin (Hb), mean corpuscular volume (MCV), platelets, leukocytes (WBC) and creatinine were determined in all samples by standard automated laboratory techniques. Reference values were established at the Department of Clinical Chemistry of the Erasmus MC in 100 healthy blood bank donors. eGFR was calculated using the original 'Modification of Diet in Renal Disease' (MDRD) study equation. 11 Ethnicity was not known to us and therefore no correction was performed as described for African-Americans. Renal dysfunction was characterized as GFR , 60 mL/min/1.73 m 2 according to MDRD guidelines.
Statistical analysis
Creatinine, GFR, MMA, vitamin B 12 and holoTC were positively skewed and therefore were 10 log-transformed. Mean and range were calculated for age, Hb, MCV, platelets and WBC. Geometric means with corresponding range were calculated for creatinine, GFR, MMA, vitamin B 12 and holoTC. MMA was dichotomized prior to ROC analysis. Test performance and ROC analysis were performed by Analyze-it (Version 2.21; Analyze-it Software Ltd, West Yorkshire, UK). Differences between areas of holoTC and vitamin B 12 were calculated by Analyze-it. ROC decision plots depicting sensitivity and specificity for different cut-off values were generated with Analyze-it. P , 0.05 was considered statistically significant. All P values were two-tailed.
Results
Characteristics of the study population are depicted in Table 1 . The mean age was 59.0 (range 19.0 -100.5) years and 38% were men ( Table 1 ). The prevalence of metabolic vitamin B 12 deficiency (i.e. MMA . 0.45 mmol/L) was 13% in our study population. Decreased vitamin B 12 ROC decision plots were used to evaluate different holoTC and vitamin B 12 cut-off values in relation to screening for metabolic vitamin B 12 deficiency in our mixed population. Metabolic vitamin B 12 deficiency was, for this analysis, characterized by MMA . 0.45 mmol/L as this was the upper limit of the 95% reference range. The ROC decision plot based on sensitivity and specificity showed optimal cut-off values of vitamin B 12 between 136 and 216 pmol/L; a lower cut-off resulted in an undesirable sensitivity of less than 50% and a higher cut-off resulted in specificity below 50% (Figure 2a ). Within this range, optimal sensitivity was obtained at a cut-off value of 180 pmol/L (e.g. above this level, the amount of true positives remained stable, whereas the amount of false positives increased rapidly). The clinical decision point of 180 pmol/L for vitamin B 12 was compared with the 2.5% lower reference value of 145 pmol/L. By increasing the cut-off value from 145 to 180 pmol/L for vitamin B 12 , the amount of true positives increased from 25 to 30, resulting in an increase in sensitivity from 53% to 64%. Specificity decreased from 81% to 64% (Figure 2a ).
The same analysis was performed for holoTC for which optimal cut-off values were obtained between 19 and (Figure 2b) . At a cut-off level of 36 pmol/L, the highest sensitivity was obtained; however, above a cut-off level of 32 pmol/L, no gain in true positives was reached despite a steep decrease in specificity (Figure 2b) . Comparison of the clinical decision point of 32 pmol/L with the lower 2.5% reference value of 21 pmol/L showed that 39 true positives were identified instead of 30 when the cut-off level of 32 pmol/L was applied for holoTC, which resulted in an increase in sensitivity from 64% to 83%. Specificity decreased accordingly from 88% till 60%.
Studies have suggested that the combination of holoTC and vitamin B 12 would have a better diagnostic accuracy in explaining MMA concentrations than holoTC or vitamin B 12 alone. 4 We evaluated diagnostic accuracy of different combinations of vitamin B 12 and holoTC and compared this with a single test result to screen for metabolic vitamin B 12 deficiency defined by MMA . 0.45 mmol/L. 12 First, we compared the gain of true positives by adding holoTC after being negative for the vitamin B 12 test (i.e. holoTC as an add-on test); this resulted in a gain of 10 true positives and seven false positives compared with the test results of the single vitamin B 12 assay. A total number of 40 true positives were identified, which is comparable with the total number of true positives identified by the single holoTC test (39 true positives). Second, we evaluated whether holoTC can be used as primary test after which all negatives are subjected to a secondary vitamin B 12 test (i.e. vitamin B 12 as an add-on test). This design resulted in a gain of one true positive and seven false positives compared with the test results of the single holoTC test.
Discussion
In this study, we validated the diagnostic accuracy of vitamin B 12 and holoTC in screening for metabolic vitamin B 12 deficiency using clinical samples from five Dutch hospitals. We confirmed that holoTC can replace vitamin B 12 in screening for metabolic vitamin B 12 deficiency in this population and determined the clinical decision point for holoTC at 32 pmol/L.
HoloTC is the biologically active form of vitamin B 12 in the blood and has been suggested to be of greater diagnostic relevance than vitamin B 12 . 6, 13 Several studies have investigated the diagnostic accuracy of vitamin B 12 and compared this with holoTC in detecting metabolic vitamin B 12 deficiency. HoloTC performed better than vitamin B 12 in five out of seven studies that compared both assays in relation to elevated MMA as an indicator of metabolic vitamin B 12 deficiency (including this study) ( Table 2) . We showed by ROC analysis that holoTC performs significantly better than vitamin B 12 in a broad range of cut-off values of MMA.
Results from our study showed that an absolute improvement of 10-20% in sensitivity can be reached by replacing vitamin B 12 by holoTC in screening for metabolic vitamin B 12 deficiency depending on the chosen cut-off value. Cut-off values of holoTC differ depending on the study population and criteria used for metabolic vitamin B 12 deficiency. 4 -7,14 Sometimes the cut-off is chosen identical to the 2.5% lower reference value of a healthy population and otherwise at a specifically chosen clinical decision point. We showed that application of the lower 2.5% reference value for holoTC (,21 pmol/L) resulted in a relatively low sensitivity of 64% with a specificity of 88%. At this cut-off level, 17 out of the 48 patients with elevated MMA would have been missed (i.e. 36% false negatives). We consider vitamin B 12 deficiency a serious condition which might result in severe irreversible neurological complications. Hence, as little patients as possible should therefore be missed (e.g. low amount of false negatives) in screening for vitamin B 12 deficiency, which requires a test with a high sensitivity. Therefore, we evaluated by ROC analysis, the highest achievable sensitivity with acceptable specificity and showed that a cut-off value of holoTC between 19 and 0.45 mmol/L. Cut-off values between 136 and 216 pmol/L resulted in a sensitivity and specificity higher than 50% (grey box). The optimal cut-off value is depicted by the arrow ( ¼ 180 pmol/L). (b) ROC decision plot based on sensitivity (solid line) and specificity (dotted line) for different cut-off values of holoTC. Cut-off values between 19 and 36 pmol/L resulted in a sensitivity and specificity higher than 50% (grey box). The optimal cut-off level is depicted by the arrow (¼32 pmol/L) 36 pmol/L is desirable, as this resulted in sensitivity and specificity both higher than 50%. The highest sensitivity was obtained at a cut-off level of 36 pmol/L; however, results from our study showed that a cut-off value above 32 pmol/L resulted in a plateau at which the gain in sensitivity was stabilized despite a steep decrease in specificity. Others used cut-off values ranging from 20 to as high as 45 pmol/L depending on the population studied. 4 -7,14 -16 Our study demonstrates that cut-off values above 36 pmol/L are undesirable, as this resulted in a specificity of less than 50%. We have chosen a cut-off value of 32 pmol/L for holoTC based upon the results of our study for screening for metabolic vitamin B 12 deficiency but we appreciate that other choices are equally tenable. In a clinical perspective, a positive test result for holoTC (,32 pmol/L) is indicative for vitamin B 12 deficiency; however, with a specificity of 60% and a prevalence of 13%, the chance of being a false positive is considerable. Therefore, in our opinion, three scenarios can be followed in this case: (i) all patients with holoTC ,32 pmol/L are treated with cobalamin; or (ii) MMA is measured as a secondary test to confirm diagnosis in all patients with holoTC , 32 pmol/L; or (iii) treatment is started in patients with holoTC , 21 pmol/L as the presence of vitamin B 12 deficiency is relatively certain at this cut-off level (e.g. specificity is 88%) and MMA is measured in patients whose holoTC is between 21 and 32 pmol/L to confirm diagnosis.
It was suggested by Miller et al. 4 that diagnostic accuracy can be increased by combining test results of vitamin B 12 and holoTC. In our study, we evaluated whether combined testing with vitamin B 12 and holoTC would result in identification of a higher number of true positives and showed that the combination of holoTC and vitamin B 12 does not increase the number of true positives that were already identified with the single holoTC assay. These results demonstrated that the combination of holoTC and vitamin B 12 does not have a additive diagnostic value, and confirms that holoTC can replace vitamin B 12 in screening for metabolic vitamin B 12 deficiency.
In summary, we confirmed that holoTC has a better test performance than vitamin B 12 and therefore can replace vitamin B 12 in detecting metabolic vitamin B 12 deficiency. Based on results from this multicentre study, we suggest applying a cut-off value of 32 pmol/L for holoTC in screening for metabolic vitamin B 12 deficiency.
DECLARATIONS
Competing interests: None. Funding: Assays for holoTC and vitamin B 12 were kindly provided by Abbott. Ethical approval: Not applicable. Guarantor: JL.
Contributorship: JL and RdJ supervised the study. RdJ, MvW, RMRH-F, ACMK, JMMP, HJA, ES, PHT, TR and JL were involved in patient recruitment. MCFJdR was involved in laboratory measurements. SGH performed data analysis and wrote the manuscript. All authors reviewed the manuscript and approved the final version of the manuscript.
